Compounds > azonafide
Page last updated: 2024-11-12

azonafide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

azonafide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9948896
CHEMBL ID290677
SCHEMBL ID3804056
MeSH IDM0244800

Synonyms (7)

Synonym
azonafide
CHEMBL290677
140917-67-5
SCHEMBL3804056
15-[2-(dimethylamino)ethyl]-15-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2,4,6,8,10,12-heptaene-14,16-dione
2-[2-(dimethylamino)ethyl]-1h-dibenzo[de,h]isoquinoline-1,3(2h)-dione
DTXSID50930944

Research Excerpts

Overview

Azonafides are a series of anthracene-based DNA intercalators which inhibit tumor cell growth in vitro. They are not affected by the multidrug resistance phenomenon (MDR)

ExcerptReferenceRelevance
"The azonafides are a series of anthracene-based DNA intercalators which inhibit tumor cell growth in vitro at low nanomolar concentrations and are not affected by the multidrug resistance phenomenon (MDR). "( Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators.
Alberts, DS; Dorr, RT; Hersh, EM; Liddil, JD; Remers, W; Sami, SM, 2001)		1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID106292Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID215072An average for IC50 values in the two solid tumor cell lines.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID103420Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID98202Antitumor activity against murine L1210 resistant cell line by using MTT assay1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID171537Cardiotoxicity measured by the ATP/protein ratio compared with untreated controls using neonatal rat heart myocyte assay.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID98203Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID216435Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID83616In vitro cytotoxicity against HT-29 (human colon adenocarcinoma) cell line.1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones.
AID106294Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID145436Antitumor activity against human ovarian OVCAR-3 cell lines.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID99359Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID98909Inhibitory activity against sensitive L1210 cell lines1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID232812Toxicity ratio of quotient of the IC50 in myocytes divided by the average IC50 for three tumor cell lines1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID309216Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B dye assay2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Highly efficient antitumor agents of heterocycles containing sulfur atom: linear and angular thiazonaphthalimides against human lung cancer cell in vitro.
AID116824Percent increase in life span when given at a dose in P388 leukemia cells of mice1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID98386Antitumor activity against murine leukemia L1210 cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID223628Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID99358Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID106293Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID52514Tested against human colon carcinoma COLO 480 cell line in vitro1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID101220Tested for percent increase in life span in L1210 leukemia cells after intraperitoneal dose of 30 mg/kg in mice1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID8483Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID216576Compound was tested against WiDr colon (sensitive) cell line in the sulforhodamine B assay.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID52494Tested against human colon carcinoma COLO 205 cell line in vitro1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID115330The percent increase in life span of compound was measured against P388 Leukemia cells in mice at at a dose of 5 mg/kg on days 1,5 and 91995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID103421Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID216451Activity against sensitive cell line of WiDr human colon tumor1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID85443Tested against human colon carcinoma HT 29 cell line in vitro1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID25315Acid dissociation constant was determined1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID221330Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID101221Tested for percent increase in life span in L1210 leukemia cells after intraperitoneal dose of 45 mg/kg in mice1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID216574Compound was tested against WiDr colon carcinoma (resistant)cell line in the sulforhodamine B assay.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID145432Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID115332The percent increase in life span of compound was measured against P388 Leukemia in mice at at a dose of 10 mg/kg on days 1,5 and 91995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID100813Tested against L1210 sensitive murine leukemia cells by MTT tetrazolium dye assay1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID106296Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID103419Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID106431Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID8690Activity against A549 cancer cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID214779Antitumor activity against human melanoma UACC375 cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID40601Tested for percent tumor growth inhibition in B16 melanoma cells after subcutaneous dose of 15 mg/kg in mice1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID145906Tested against OVCAR-3 human ovarian cancer cells by sulforhodamine B (SRB) assay1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID106430Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID232811Toxicity ratio determined by the quotient of IC50 values in the myocytes divided by the average value in the three tumor lines.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID107214Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID98384Antitumor activity against sensitive L1210 murine leukemia cell lines.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID227708Average mean for IC50 values in the four cell lines (OVCAR-3,OVCAR3,L1210 sensitive,L1210 resistant)1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID216595Activity against human colon carcinoma sensitive WiDr cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID232810The quotient of the IC50 is the myocytes divided by the mean IC50 in the four cell lines (OVCAR-3,OVCAR3,L1210 sensitive,L1210 resistant)1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID226658An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID214780Tested against UACC375 human melanoma cancer cells by sulforhodamine B (SRB) assay1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID102185Tested against human colon carcinoma LoVo cell line in vitro1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID170463Cardiotoxicity by a neonatal rat heart myocyte assay1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID100812Tested against L1210 resistant murine leukemia cells by MTT tetrazolium dye assay1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID101219Tested for percent increase in life span in L1210 leukemia cells after intraperitoneal dose of 15 mg/kg in mice1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID216450Activity against resistant cell line of WiDr human colon tumor1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID145445Inhibitory activity against OVCAR-3 cell line1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID98908Inhibitory activity against resistant murine leukemia L1210 cell lines.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID232808The quotient of the IC50 in the myocytes divided by the mean IC50 in the three cell lines1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID80370Tested against human colon carcinoma HCT 15 cell line in vitro1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID97256Compound was tested against L1210 leukemia cell line in mice at 15 mg/kg dosage.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID214778Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID153423Compound was tested against P388 leukemia cell line in mice at 15 mg/kg dosage.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID221144Tested for in vitro for cardiotoxicity by performing neonatal rat heart myocyte assay method1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID101222Tested for percent increase in life span in L1210 leukemia cells after intraperitoneal dose of 5 mg/kg in mice1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent.
AID216596Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID32544Inhibitory activity against AUC375 cell line1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID196905Cardiotoxicity was measured by using Neonatal rat heart myocyte assay1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID216434Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Analogues of amonafide and azonafide with novel ring systems.
AID115334The percent increase in life span of compound was measured against P388 Leukemia in mice at at a dose of 15 mg/kg on days 1,5 and 91995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID39737Compound was tested against sc B16 melanoma cell line in mice at 15 mg/kg dosage.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (61.54)18.2507
2000's4 (30.77)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.72 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.91406-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.9140dihydroxyanthraquinoneanalgesic;
antineoplastic agent
anthracene
acene : A polycyclic aromatic hydrocarbon consisting of fused benzene rings in a rectilinear arrangement.. acenes : Polycyclic aromatic hydrocarbons consisting of fused benzene rings in a rectilinear arrangement and their substitution derivatives.		210acene;
anthracenes;
ortho-fused tricyclic hydrocarbon
thiazoles
[no description available]		1.99101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		3.690isoquinolines
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		1.9910organic bromide saltcolorimetric reagent;
dye
naphthalimides
Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.		9.6180
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.9140divalent inorganic anion;
phosphite ion
mitonafide
[no description available]		1.9910
elinafide
elinafide: structure given in first source		1.9910
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		210
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		01.9810
Cardiac Diseases
[description not available]		01.9810
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.3920
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		01.9810
Leukemia L 1210
[description not available]		01.9810
B16 Melanoma
[description not available]		01.9810
Cancer of Ovary
[description not available]		01.9810
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		01.9810
Cancer of Lung
[description not available]		02.0310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0310
Breast Cancer
[description not available]		02.110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.110
Benign Neoplasms
[description not available]		03.3420
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.3420